In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety.
Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece.
We lifted our Eli Lilly price target Friday to $630 per share, up from $600.
Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market.
The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.
Persons:
Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast
Organizations:
Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty
Locations:
New York, Danish, Lilly, U.S, Indianapolis , Indiana